Stock Screener App

Gratuito -

Installare

31.95

22.46% 5.905

Cassava Sciences Inc (SAVA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché SAVA Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Cassava Sciences Inc Borsa (SAVA) Ultime notizie

January 2025 Options Now Available For Cassava Sciences (SAVA) - Nasdaq

Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year? - MSN

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer - citybiz

Cassava Sciences, Inc. Appoints Freda Nassif as Chief Commercial Officer - Marketscreener.com

Cassava Sciences stock up on Alzheimer’s update (SAVA:NASDAQ) - Seeking Alpha

What Makes Cassava Sciences (SAVA) a New Buy Stock - MSN

A High-potential Bull Put Strategy on Cassava Sciences - MSN

A High-Potential Bull Put Strategy On Cassava Sciences - Barchart

Cassava Sciences Inc (SAVA-Q) QuotePress Release - The Globe and Mail

Anavex, Cassava Sciences, Panax Ginseng, And Long-Term Treatment Of Alzheimer's Disease - Seeking Alpha

How To Trade (SAVA) - Stock Traders Daily

Cassava Sciences, Inc. (NASDAQ:SAVA) Q3 2024 Earnings Call Transcript - Insider Monkey

Cassava Sciences (NASDAQ:SAVA) Issues Quarterly Earnings Results - MarketBeat

Cassava Sciences (NASDAQ:SAVA) Given "Buy" Rating at HC Wainwright - MarketBeat

Cassava Sciences Q3 2024 Earnings Preview - MSN

Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla? - Benzinga

Another U.S. biotech based on Chinese science - STAT

Cassava Sciences: With Almost Half The Float Shorted, Results Could Be Interesting - Seeking Alpha

Cassava Sciences nears Alzheimer's drug trial results By Investing.com - Investing.com Canada

Cassava Sciences’ Q3 2024: Financials and Alzheimer’s Trials Progress - TipRanks

Cassava Sciences: Pivotal Alzheimer’s Data May Push Stock Toward Book Value (SAVA) - Seeking Alpha

Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh (NASDAQ:SAVA) - Seeking Alpha

Looking At Cassava Sciences's Recent Unusual Options Activity - Benzinga

Cassava Sciences nears Alzheimer's drug trial results - Investing.com India

Cassava Sciences stock in focus after earnings (SAVA:NASDAQ) - Seeking Alpha

Cassava Sciences Reports Q3 2024 Financial and Operating Results - The Manila Times

Cassava Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Cassava Sciences (NASDAQ:SAVA) Trading Down 5.8%Should You Sell? - MarketBeat

Unpacking the Latest Options Trading Trends in Cassava Sciences - Benzinga

Analysts Believe Cassava Sciences Now Has 300% Upside From Here - MSN

Cassava Sciences (SAVA) Scheduled to Post Earnings on Thursday - MarketBeat

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024 - GlobeNewswire

International Assets Investment Management LLC Makes New Investment in Cassava Sciences, Inc. (NASDAQ:SAVA) - MarketBeat

Institutions along with individual investors who hold considerable shares inCassava Sciences, Inc. (NASDAQ:SAVA) come under pressure; lose 6.7% of holdings value - Yahoo Finance

Long Term Trading Analysis for (SAVA) - Stock Traders Daily

HC Wainwright & Co. Upgrades Cassava Sciences (SAVA) - MSN

Cassava Sciences Options Trading: A Deep Dive into Market Sentiment - Benzinga

Institutions profited after Cassava Sciences, Inc.'s (NASDAQ:SAVA) market cap rose US$72m last week but individual investors profited the most - Simply Wall St

(SAVA) Proactive Strategies - Stock Traders Daily

Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge - Insider Monkey

Cassava Sciences (NASDAQ:SAVA) Trading 5.1% HigherWhat's Next? - MarketBeat

SMMT

$18.98

1.80%

INCY

$70.68

0.42%

MRNA

$38.38

3.49%

UTHR

$369.83

1.48%

BGNE

$196.58

0.88%

BNTX

$102.64

0.27%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters